Satellos Q2 2026 loss widens as R&D spending rises on SAT-3247 BASECAMP, TRAILHEAD trials, company says
Reuters2026/08/13 21:21- Satellos posted a net loss of USD 11.72 million in Q2 2026, widened from USD 5.61 million as spending rose.
- R&D expense climbed to USD 9.64 million from USD 4.44 million, driven by BASECAMP and TRAILHEAD clinical activity.
- Higher manufacturing work and preclinical safety studies also lifted R&D costs, alongside increased headcount supporting expanded development.
- G&A expense increased to USD 2.53 million from USD 1.93 million, reflecting higher professional fees and operating costs tied to Nasdaq reporting.
- Cash and short-term investments totaled USD 61.84 million at June 30, 2026, up from USD 27.71 million following USD 51.9 million net offering proceeds.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japanese Yen consolidates near August highs vs USD as hawkish BoJ, Fed bets clash
The 10-year U.S. Treasury yield climbs to 4.8%, erasing the dividend advantage of utility stocks; the sector’s rebound depends on interest rate stabilization rather than technical signals.
As U.S. Treasury yields continue to climb, the American utilities sector is experiencing a significant pullback—a rise in yields not only erodes the relative appeal of the sector’s dividends but also raises financing costs for the most capital-intensive industries within this market.
Euro holds gains above 1.1600 despite robust US jobs data, traders eye ECB rate decision
Crypto prices
More
